China Advances Two Coronavirus Vaccines Into Phase III
Brazil, UAE Among First Countries For Tests
Executive Summary
Chinese state-owned company Sinopharm has started a Phase III coronavirus vaccine study in Abu Dhabi, while another Chinese firm, Sinovac, has commenced its trial with partner Butantan in Brazil. Meanwhile, regulators in Beijing have started an audit process to ensure regulatory compliance.
You may also be interested in...
Coronavirus Update: BioNTech And Fosun Launch Vaccine Trial In China
The study is designed to support the regulatory approval process in China and confirm that the safety and immunogenicity profile observed in German and US trials is comparable to that of Chinese participants, according to BioNTech.
Quick Listen: Scrip’s Five Must-Know Things
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.
China’s Coronavirus Vaccine Ambition Hampered By Lack Of Guidance On Overseas Clinical Data
As two Chinese-developed vaccines against COVID-19 enter the final stage of testing in Latin America and the Middle East, a lack of guidance on using data obtained outside China could potentially pose challenges to regulatory approvals at home.
Need a specific report? 1000+ reports available
Buy Reports